<DOC>
	<DOCNO>NCT00043888</DOCNO>
	<brief_summary>Antiretroviral Therapy ( ART ) naive subject enrol clinical research study test safety tolerability fosamprenavir without ritonavir combination TRIZIVIR COMBIVIR . Subjects receive 24 week therapy .</brief_summary>
	<brief_title>Study Explore Safety And Tolerability Fosamprenavir With Without Ritonavir Combination With TRIZIVIR COMBIVIR</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Lab result Screening viral load ( HIV1 RNA ) great equal 1,000 copy per mL . Lab result Screening CD4 cell count great equal 100 cell per microliter . Antiretroviral therapy naive ( prior therapy allow ) . Male female 13 year age old ( 18 year age old accord local requirement ) . Female subject must nonchild bear potential ( i.e . physiologically incapable become pregnant , include woman postmenopausal ) childbearing potential negative blood pregnancy test screen agree use prove barrier method contraception ( e.g . spermicide plus condom ) study period . Hormonal contraceptive consider sufficient form contraception study . All subject participate study counsel practice safe safer sex . Able understand provide write informed consent participate trial . Parental guardian consent must also obtain subject age 18 year . Prior history receive antiretroviral therapy . An active HIV Associated Disease ( Center Disease Control Category C ) within 28 day study drug administration . Any sudden onset sharp rise laboratory abnormality ( include abnormally high laboratory value ) Screening cause investigator opinion subject participate study investigational compound . Subjects laboratory result estimate creatinine clearance le 40 ml per minute within 28 day study drug administration . Laboratory result serum aminotransferase ( AST , ALT ) level elevate great five ten time ( ) upper limit normal range within 28 day prior study drug administration . Pregnant lactating woman . History clinically relevant pancreatitis hepatitis within 6 month study drug administration . Presence serious medical condition ( e.g. , diabetes , cardiac dysfunction , hepatitis ) , opinion investigator , might compromise safety subject . Presence malabsorption syndrome gastrointestinal dysfunction might interfere drug absorption render subject unable take oral medication . History drug allergy , opinion investigator , contraindicate subject 's participation study . Treatment radiation therapy cytotoxic chemotherapeutic agent within 28 day study drug administration anticipate need treatment study . Treatment immunomodulating agent ( systemic corticosteroid , interleukin , interferon ) agent know antiHIV activity ( hydroxyurea foscarnet ) within 28 day study drug administration . Treatment HIV vaccine within 3 month study drug administration . Treatment select medication within 28 day prior receive study medication anticipate need study . Current alcohol illicit drug use , opinion investigator , may interfere subject 's ability comply requirement study . Note : Subjects stabilize methadone consider participation . Treatment investigational drug therapy within 28 day prior Day 1 , anticipate need treatment study . Treatments available Treatment IND expandedaccess mechanism evaluate casebycase basis . Other inclusion exclusion criterion determine investigator sponsor study .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>fosamprenavir</keyword>
	<keyword>ritonavir</keyword>
	<keyword>COMBIVIR</keyword>
	<keyword>TRIZIVIR</keyword>
	<keyword>abacavir</keyword>
	<keyword>lamivudine</keyword>
	<keyword>zidovudine</keyword>
	<keyword>HIV</keyword>
	<keyword>protease inhibitor</keyword>
</DOC>